CSPC Pharmaceutical Group Crecimiento futuro
Future controles de criterios 1/6
Se prevé un crecimiento anual de los beneficios y los ingresos de CSPC Pharmaceutical Group de 2.7% y 3.8% por año respectivamente. Se prevé que el BPA crezca en un 2% al año. Se espera que la rentabilidad financiera sea de 10.3% en 3 años.
Información clave
2.7%
Tasa de crecimiento de los beneficios
2.0%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 10.8% |
| Tasa de crecimiento de los ingresos | 3.8% |
| Rentabilidad financiera futura | 10.3% |
| Cobertura de analistas | Good |
| Última actualización | 19 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think
May 29
Recent updates
Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount?
Nov 15Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Oct 16Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%
Sep 30CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected
Aug 08Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Jun 17CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think
May 29CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14
May 21CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14
Apr 29There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price
Apr 22CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14
Apr 01CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 22Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E
Jan 04Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?
Oct 22Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?
Sep 21CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price
Jul 09Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?
Jun 20CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 01CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11
Apr 04CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price
Mar 12Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 33,915 | 5,953 | 5,192 | N/A | 25 |
| 12/31/2025 | 32,273 | 5,626 | 4,680 | N/A | 28 |
| 12/31/2024 | 30,605 | 5,209 | 4,270 | N/A | 24 |
| 9/30/2024 | 30,271 | 5,157 | N/A | N/A | N/A |
| 6/30/2024 | 31,654 | 5,927 | 2,672 | 4,284 | N/A |
| 3/31/2024 | 32,380 | 6,057 | N/A | N/A | N/A |
| 12/31/2023 | 31,450 | 5,873 | 2,290 | 4,179 | N/A |
| 9/30/2023 | 31,306 | 6,118 | N/A | N/A | N/A |
| 6/30/2023 | 31,407 | 6,092 | 1,934 | 4,690 | N/A |
| 3/31/2023 | 31,116 | 6,116 | N/A | N/A | N/A |
| 12/31/2022 | 30,937 | 6,091 | 4,922 | 7,627 | N/A |
| 9/30/2022 | 30,721 | 5,738 | N/A | N/A | N/A |
| 6/30/2022 | 29,655 | 5,509 | 4,094 | 6,151 | N/A |
| 3/31/2022 | 29,007 | 5,538 | N/A | N/A | N/A |
| 12/31/2021 | 27,867 | 5,605 | 2,887 | 4,637 | N/A |
| 9/30/2021 | 26,369 | 5,977 | N/A | N/A | N/A |
| 6/30/2021 | 26,175 | 5,908 | 5,865 | 7,053 | N/A |
| 3/31/2021 | 25,551 | 5,472 | N/A | N/A | N/A |
| 12/31/2020 | 24,942 | 5,160 | 5,362 | 6,740 | N/A |
| 9/30/2020 | 24,558 | 4,421 | N/A | N/A | N/A |
| 6/30/2020 | 23,515 | 4,150 | 3,129 | 4,614 | N/A |
| 3/31/2020 | 22,735 | 3,922 | N/A | N/A | N/A |
| 12/31/2019 | 22,103 | 3,714 | 1,835 | 3,784 | N/A |
| 9/30/2019 | 21,335 | 3,625 | N/A | N/A | N/A |
| 6/30/2019 | 20,135 | 3,454 | 1,370 | 3,743 | N/A |
| 3/31/2019 | 18,835 | 3,294 | N/A | N/A | N/A |
| 12/31/2018 | 17,717 | 3,081 | 1,922 | 3,795 | N/A |
| 9/30/2018 | 16,877 | 2,905 | N/A | N/A | N/A |
| 6/30/2018 | 15,729 | 2,734 | N/A | 3,352 | N/A |
| 3/31/2018 | 13,959 | 2,443 | N/A | N/A | N/A |
| 12/31/2017 | 12,877 | 2,307 | N/A | 2,738 | N/A |
| 9/30/2017 | 12,203 | 2,195 | N/A | N/A | N/A |
| 6/30/2017 | 11,659 | 2,068 | N/A | 2,811 | N/A |
| 3/31/2017 | 11,383 | 1,979 | N/A | N/A | N/A |
| 12/31/2016 | 11,075 | 1,881 | N/A | 2,611 | N/A |
| 9/30/2016 | 10,439 | 1,711 | N/A | N/A | N/A |
| 6/30/2016 | 10,118 | 1,607 | N/A | 2,147 | N/A |
| 3/31/2016 | 9,656 | 1,473 | N/A | N/A | N/A |
| 12/31/2015 | 9,545 | 1,395 | N/A | 1,884 | N/A |
| 9/30/2015 | 9,284 | 1,305 | N/A | N/A | N/A |
| 6/30/2015 | 9,072 | 1,192 | N/A | 1,192 | N/A |
| 3/31/2015 | 8,919 | 1,126 | N/A | N/A | N/A |
| 12/31/2014 | 8,762 | 1,015 | N/A | 1,445 | N/A |
| 9/30/2014 | 8,423 | 896 | N/A | N/A | N/A |
| 6/30/2014 | 8,197 | 849 | N/A | 1,059 | N/A |
| 3/31/2014 | 8,001 | 814 | N/A | N/A | N/A |
| 12/31/2013 | 7,768 | 760 | N/A | 636 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (2.7% al año) de 1093 es superior a la tasa de ahorro (2.3%).
Beneficios vs. Mercado: Se prevé que los beneficios (2.7% al año) de 1093 crezcan menos que el mercado Hong Kong (11.6% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de 1093 crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (3.8% al año) de 1093 crezcan más despacio que el mercado de Hong Kong (7.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 3.8% al año) de 1093 crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de 1093 sea baja dentro de 3 años (10.3%).